NL-OMON50023
Completed
Not Applicable
Heart Failure with Preserved Ejection Fraction (HFpEF), a prospective cohort - HFpEF cohort
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- hartaandoeningen, falen van de hartfunctie
- Sponsor
- Academisch Medisch Centrum
- Enrollment
- 201
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
Trial ended prematurely
Investigators
Eligibility Criteria
Inclusion Criteria
- •All patients referred with exertional dyspnea to the HFpEF clinic from the
- •general HF, general cardiology outpatient clinic or directly from their general
- •practitioners above 18 years that have the ability to give the informed consent
- •and sign it will be included in the cohort and blood and urine samples for the
- •biobank will be obtained. , 20 hypertensive control patients will be included.
- •These are their inclusion criteria:
- •o Age \> 50 years
- •o Estimated glomerular filtration reserve (eGFR) \>30 ml/min
- •o Body weight\<130kg
- •o No coronary artery disease (CAD; coronary stenosis\>70% or history of CABG)
Exclusion Criteria
- •\- Inability to give informed consent or refusal to participate in the study
- •\- Age \<18 years.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Whole blood thrombin generation, platelet activation test and platelet-monocyte complex formation to predict hypercoagulability in patients with multiple myelomacancer of plasma cellsPlasma cell myeloma10018865NL-OMON48375Synapse Research Institute42
Completed
Not Applicable
Superior capsular reconstruction of irreparable degenerative rotator cuff tears of the shoulder: a multi-center,comparative, prospective, observational follow-up studyNL-OMON48664Viecuri Medisch Centrum voor Noord-Limburg17
Completed
Not Applicable
Validation of the Dutch version of the Hip Outcome ScoreNL-OMON47747Reinier de Graaf Groep136
Completed
Not Applicable
A Phase 1/1b First-in-human Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of SAR439459 Administered Intravenously as Monotherapy and in Combination with cemiplimab in Adult Patients with Advanced Solid TumorsAdvanced solid tumors10027655NL-OMON55468Genzyme Europe BV12
Completed
Phase 3
Phase III, pivotal, multicentre, randomised, double-blind controlled Study to evaluate the Efficacy and Safety of Autologous Osteoblastic Cells (PREOB®) Implantation in Early Stage Non Traumatic Osteonecrosis of the Femoral Head.NL-OMON45063Bone Therapeutics6